ProQR Therapeutics (PRQR) Common Equity (2014 - 2025)

ProQR Therapeutics' Common Equity history runs 12 years deep, the most recent figure standing at $57.5 million for Q4 2025.

• In Q4 2025, Common Equity fell 39.27% year-over-year to $57.5 million; the TTM figure through Dec 2025 stood at $57.5 million (down 39.27% YoY), while the FY2025 annual figure was $57.5 million, down 39.27% from the prior year.
• Common Equity came in at $57.5 million for Q4 2025 at ProQR Therapeutics, down from $94.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $151.0 million in Q3 2021 to a low of $59322.7 in Q1 2021.
• A 5-year average of $80.5 million and a median of $66.6 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 99.93% in 2021 and jumped 189502.52% in 2022, its largest moves.
• ProQR Therapeutics' Common Equity stood at $130.5 million in 2021, then plunged by 47.88% to $68.0 million in 2022, then slumped by 34.54% to $44.5 million in 2023, then jumped by 112.5% to $94.6 million in 2024, then slumped by 39.27% to $57.5 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $57.5 million, $94.6 million, and $44.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison